Johnson & Johnson’s TAR-200 for Bladder Cancer Granted FDA Priority Review
July 21, 2025
NDA for TAR-200 targets high-risk non-muscle invasive bladder cancer, highlighting potential to transform treatment for patients unresponsive to BCG therapy